Genmab announces results of Ofatumumab phase II study in MS

Kesimpta is a subcutaneously injected anti CD20 monoclonal antibody approved for RRMS and active progressive MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Genmab announces results of Ofatumumab phase II study in MS

Post by MSUK » Mon Sep 13, 2010 1:27 am

Image

Genmab announces 48 week results from a Phase II study of ofatumumabin RRMS.

Genmab A/S announced encouraging results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).

A total of 38 patients were included in this double-blind, dose escalation trial. Patients were randomized to receive two infusions of 100 mg, 300 mg or 700 mg of ofatumumab or placebo. After 24 weeks, the patients randomized to placebo were treated with ofatumumab and patients who were treated with ofatumumab received placebo. All patients were then followed for an additional 24 weeks. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Kesimpta (Ofatumumab)”